Guidelines Development Group

The objective of the Guidelines Development Group (GDG) is to develop evidence-based European Guidelines for breast cancer screening and diagnosis for screening and diagnosis.

The GDG will follow the GRADE approach in defining the healthcare question of interest (population of interest, interventions to be compared and patient-relevant outcomes- PICO), synthesizing the evidence and developing the recommendations for the Guidelines. This will be carried out within virtual working environments and in meetings organised every three months.

An external contractor, CCIb –Iberoamerican Cochrane Centre, supports the GDG for their tasks from literature review to drafting of recommendations.

Members and external experts

Miranda Langendam

Miranda Langendam

GDG External Expert

Miranda W. Langendam, PhD.Department Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center/University of Amsterdam

Dr Miranda Langendam is an epidemiologist with keen interest in evidence-based health care. She was trained in biomedical sciences and worked as researcher for several academic and governmental organisations on a wide range of health care questions (public health and clinical care).

Since 2008 she is assistant professor at the Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center/University of Amsterdam. She was  senior staff member of Cochrane Netherlands from 2008 to 2014.

The focus of her work is developing, applying and teaching evidence synthesis methodology, always in close collaboration with clinicians and other health care professionals. She has been involved in many (commissioned) systematic reviews and evidence-based guidelines, in the role of developer, project lead and methodology consultant. From 2011-2015 she was co-investigator of the GRADE/DECIDE project (, in the work package on developing recommendations for medical tests. Currently she advises the National Health Care Institute on how to use GRADE for coverage decisions. She is an active member of Cochrane and the GRADE working group, co-chair of the Dutch GRADE Network and executive board member of the Netherlands Epidemiological Society. 

Declaration of interests